Under the collaborative agreement, PacificGMP produced master cell and baculovirus banks and will provide storage services under cGMP (current good manufacturing practices) standards for LigoCyte’s norovirus vaccine program.
Furthermore, PacificGMP conducted the services under an accelerated timeline.
Leigh Pierce, president of PacificGMP, said: “We are pleased that LigoCyte chose PacificGMP to produce the master cell and baculovirus banks that will be used to produce their next-generation, intra-muscular norovirus vaccine candidate.
“The timeline specified in this agreement further demonstrates the time saving advantages of single-use technology as we were able to quickly initiate this project in order to assist LigoCyte in maintaining its program schedule.”